Avecho Biotechnology Ltd (ASX: AVE) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Avecho Biotechnology Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$34.90 million
P/E Ratio
17.99
Dividend Yield
0.00%
Shares Outstanding
3.67 billion
Earnings per share
-0.001
Dividend per share
N/A
Year To Date Return
-11.11%
Earnings Yield
5.56%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Avecho Biotechnology Ltd (ASX: AVE)
Latest News
Healthcare Shares
Do ASX biotech shares offer 'good buying' after the sell-off? Experts weigh in
Share Market News
Avecho (ASX:AVE) share price rockets 83% on milestone announcement
AVE ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Avecho Biotechnology Ltd
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.
AVE Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 09 Apr 2026 | $0.01 | $0.00 | 0.00% | 1,777,191 | $0.01 | $0.01 | $0.01 |
| 08 Apr 2026 | $0.01 | $0.00 | 0.00% | 953,335 | $0.01 | $0.01 | $0.01 |
| 07 Apr 2026 | $0.01 | $0.00 | 0.00% | 2,263,259 | $0.01 | $0.01 | $0.01 |
| 02 Apr 2026 | $0.01 | $0.00 | 0.00% | 8,203,886 | $0.01 | $0.01 | $0.01 |
| 01 Apr 2026 | $0.01 | $0.00 | 0.00% | 2,418,004 | $0.01 | $0.01 | $0.01 |
| 31 Mar 2026 | $0.01 | $0.00 | 0.00% | 9,283,223 | $0.01 | $0.01 | $0.01 |
| 30 Mar 2026 | $0.01 | $0.00 | 0.00% | 8,319,939 | $0.01 | $0.01 | $0.01 |
| 27 Mar 2026 | $0.01 | $0.00 | 0.00% | 189,565 | $0.01 | $0.01 | $0.01 |
| 26 Mar 2026 | $0.01 | $0.00 | 0.00% | 78,133 | $0.01 | $0.01 | $0.01 |
| 25 Mar 2026 | $0.01 | $0.00 | 0.00% | 8,700,423 | $0.01 | $0.01 | $0.01 |
| 24 Mar 2026 | $0.01 | $0.00 | 0.00% | 7,860,285 | $0.01 | $0.01 | $0.01 |
| 23 Mar 2026 | $0.01 | $0.00 | 0.00% | 3,397,437 | $0.01 | $0.01 | $0.01 |
| 20 Mar 2026 | $0.01 | $0.00 | 0.00% | 16,756,320 | $0.01 | $0.01 | $0.01 |
| 19 Mar 2026 | $0.01 | $0.00 | 0.00% | 3,545,000 | $0.01 | $0.01 | $0.01 |
| 18 Mar 2026 | $0.01 | $0.00 | 0.00% | 18,953,943 | $0.01 | $0.01 | $0.01 |
| 17 Mar 2026 | $0.01 | $0.00 | 0.00% | 4,657,807 | $0.01 | $0.01 | $0.01 |
| 16 Mar 2026 | $0.01 | $0.00 | 0.00% | 765,676 | $0.01 | $0.01 | $0.01 |
| 13 Mar 2026 | $0.01 | $0.00 | 0.00% | 7,216,651 | $0.01 | $0.01 | $0.01 |
| 12 Mar 2026 | $0.01 | $0.00 | 0.00% | 6,961,899 | $0.01 | $0.01 | $0.01 |
| 11 Mar 2026 | $0.01 | $0.00 | 0.00% | 969,677 | $0.01 | $0.01 | $0.01 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 27 May 2025 | Gregory (Greg) Collier | Issued | 6,338,595 | $31,692 |
Issue of options.
|
| 27 May 2025 | Ross Murdoch | Issued | 3,169,298 | $15,846 |
Issue of options.
|
| 27 May 2025 | Matthew McNamara | Issued | 3,169,298 | $15,846 |
Issue of options.
|
| 27 May 2025 | Katherine(Kathy) Connell | Issued | 3,169,298 | $15,846 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Gregory (Greg) Collier | Non-Executive ChairmanNon-Executive Director | Apr 2019 |
Dr Collier has more than 25 years of experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialisation. He has led the planning and execution of multiple commercial transactions including in and out licensing deals and M&A activities, and he has taken a drug from discovery through to regulatory approval.
|
| Dr Ross Murdoch | Non-Executive Director | Apr 2015 |
Dr Murdoch has over 30 years of experience as a leader within the global healthcare, pharmaceutical and biotechnology industries. He has held senior management and executive positions in Australia, the USA and Europe, with responsibility for the strategy, development and commercialisation of products, product portfolios and the building and rebuilding of new and existing businesses.
|
| Mr Matthew Patrick McNamara | Non-Executive Director | Jan 2020 |
Mr McNamara has over 35 years of executive and funds management experience in the healthcare and medical sciences sectorIn 2003, he founded BioBridge Australia, a biotechnology commercialisation advisory company and advised several public biotechnology / investment companies.
|
| Ms Katherine(Kathy) Ellen Danielle Connell | Non-Executive Director | Apr 2024 |
Ms Connell has held senior executive leadership positions in biotechnology, pharmaceutical, medical device and consumer health sectors specialising in business development, licensing, acquisitions and venture investment, as well as having worked in healthcare and lifesciences executive search and management consulting with Korn Ferry.
|
| Ms Melanie Jaye Leydin | Chief Financial OfficerCompany Secretary | Dec 2018 |
-
|
| Dr Paul Gavin | Chief Executive Officer | May 2020 |
-
|
| Paul Gavin | Chief Executive Officer |
-
|
|
| Melanie Jaye Leydin | Chief Financial OfficerCompany Secretary |
-
|
|
| Roksan Libinaki | Chief Operating Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Paradyce Pty Ltd <The Paradyce A/C> | 349,133,188 | 9.50% |
| Ms Chunyan Niu | 188,700,000 | 5.14% |
| Rosscope Pty Ltd <Ross Copeland Family A/C> | 89,973,986 | 2.45% |
| HSBC Custody Nominees (Australia) Limited | 60,723,184 | 1.65% |
| Berne No 132 Nominees Pty Ltd <791994 A/C> | 50,000,000 | 1.36% |
| Mr Joshua Gordon | 50,000,000 | 1.36% |
| Mr Brandon Armon Batagol | 44,532,406 | 1.21% |
| Jawess Pty Ltd <Kent Family Super Fund A/C> | 42,814,606 | 1.17% |
| BNP Paribas Norns Pty Ltd | 39,471,473 | 1.07% |
| Ice Cold Investments Pty Ltd <G & J Brown Super Fund A/C> | 35,000,000 | 0.95% |
| Greensea Investments Pty Ltd | 35,000,000 | 0.95% |
| Dr Maurice Arthur Trewhella and Mrs Elizabeth Trewhella <Simpetejen Super Fund A/C> | 30,000,000 | 0.82% |
| Servbond Pty Limited <Servbond Pty Ltd S/F A/C> | 29,615,982 | 0.81% |
| Mr Andrew James Caddy | 28,000,000 | 0.76% |
| Dr Stephen Dennis Gipps | 25,500,000 | 0.69% |
| King Corporate Pty Ltd | 25,333,333 | 0.69% |
| Mr David Segal | 25,000,000 | 0.68% |
| Citicorp Nominees Pty Limited | 24,646,941 | 0.67% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 24,516,599 | 0.67% |
| Zico Investments Pty Ltd | 24,000,000 | 0.66% |
